Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00602667 · OUTCOME

Number of Participants With Endocrinopathy

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma · Source last updated 2026-05-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
End of induction therapy (approximately 16 weeks from start of treatment), end of therapy (approximately 48 weeks from start of treatment), and 6, 12, 24, 36, 48, and 60 months off therapy

What was measured

Endocrine screening and growth hormone (GH) testing were done in consenting intermediate risk patients at the end of induction therapy, the end of all therapy, and at 6, 12, 24, 36, 48, and 60 months off therapy. Endocrinopathy was defined as the presence of central hypothyroidism (free T4 concentration below normal with low or normal TSH concentration), growth hormone deficiency (peak growth hormone concentration below 5 ng/mL on dynamic testing), or ACTH deficiency (cortisol concentration below 14 ug/dL after low dose cosyntropin stimulation). Numbers of participants with endocrinopathy at each time point are reported. Please note the small numbers of participants with available data.

Analysis population: Endocrine screening and growth hormone (GH) testing were done in consenting intermediate risk patients.

Groups in this outcome

Low-Risk Group

Patients with gross total resection (GTR)/no evidence of metastatic (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.

Intermediate-Risk Group

Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.

High-Risk Group

Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Low-Risk Group0
Intermediate-Risk Group24
High-Risk Group0

Reported measurements

End of induction-number with endocrinopathy

Analysis denominator · Participants

GroupSource count
Low-Risk Group0
Intermediate-Risk Group13
High-Risk Group0
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Intermediate-Risk Group0Not reportedNot reportedNot reportedNot reported
End of therapy-number with endocrinopathy

Analysis denominator · Participants

GroupSource count
Low-Risk Group0
Intermediate-Risk Group8
High-Risk Group0
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Intermediate-Risk Group0Not reportedNot reportedNot reportedNot reported
6-months off therapy-number with endocrinopathy

Analysis denominator · Participants

GroupSource count
Low-Risk Group0
Intermediate-Risk Group3
High-Risk Group0
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Intermediate-Risk Group0Not reportedNot reportedNot reportedNot reported
12-months off therapy-number with endocrinopathy

Analysis denominator · Participants

GroupSource count
Low-Risk Group0
Intermediate-Risk Group1
High-Risk Group0
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Intermediate-Risk Group0Not reportedNot reportedNot reportedNot reported
24-months off therapy-number with endocrinopathy

Analysis denominator · Participants

GroupSource count
Low-Risk Group0
Intermediate-Risk Group6
High-Risk Group0
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Intermediate-Risk Group2Not reportedNot reportedNot reportedNot reported
36-months off therapy-number with endocrinopathy

Analysis denominator · Participants

GroupSource count
Low-Risk Group0
Intermediate-Risk Group1
High-Risk Group0
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Intermediate-Risk Group0Not reportedNot reportedNot reportedNot reported
48-months off therapy-number with endocrinopathy

Analysis denominator · Participants

GroupSource count
Low-Risk Group0
Intermediate-Risk Group1
High-Risk Group0
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Intermediate-Risk Group0Not reportedNot reportedNot reportedNot reported
60-months off therapy-number with endocrinopathy

Analysis denominator · Participants

GroupSource count
Low-Risk Group0
Intermediate-Risk Group1
High-Risk Group0
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Intermediate-Risk Group1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG001
        value
        0
    denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        13
      3. group Id
        OG002
        value
        0
      units
      Participants
    title
    End of induction-number with endocrinopathy
  2. categories
    1. measurements
      1. group Id
        OG001
        value
        0
    denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        8
      3. group Id
        OG002
        value
        0
      units
      Participants
    title
    End of therapy-number with endocrinopathy
  3. categories
    1. measurements
      1. group Id
        OG001
        value
        0
    denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        3
      3. group Id
        OG002
        value
        0
      units
      Participants
    title
    6-months off therapy-number with endocrinopathy
  4. categories
    1. measurements
      1. group Id
        OG001
        value
        0
    denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        1
      3. group Id
        OG002
        value
        0
      units
      Participants
    title
    12-months off therapy-number with endocrinopathy
  5. categories
    1. measurements
      1. group Id
        OG001
        value
        2
    denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        6
      3. group Id
        OG002
        value
        0
      units
      Participants
    title
    24-months off therapy-number with endocrinopathy
  6. categories
    1. measurements
      1. group Id
        OG001
        value
        0
    denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        1
      3. group Id
        OG002
        value
        0
      units
      Participants
    title
    36-months off therapy-number with endocrinopathy
  7. categories
    1. measurements
      1. group Id
        OG001
        value
        0
    denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        1
      3. group Id
        OG002
        value
        0
      units
      Participants
    title
    48-months off therapy-number with endocrinopathy
  8. categories
    1. measurements
      1. group Id
        OG001
        value
        1
    denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        1
      3. group Id
        OG002
        value
        0
      units
      Participants
    title
    60-months off therapy-number with endocrinopathy
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      24
    3. group Id
      OG002
      value
      0
    units
    Participants
description
Endocrine screening and growth hormone (GH) testing were done in consenting intermediate risk patients at the end of induction therapy, the end of all therapy, and at 6, 12, 24, 36, 48, and 60 months off therapy. Endocrinopathy was defined as the presence of central hypothyroidism (free T4 concentration below normal with low or normal TSH concentration), growth hormone deficiency (peak growth hormone concentration below 5 ng/mL on dynamic testing), or ACTH deficiency (cortisol concentration below 14 ug/dL after low dose cosyntropin stimulation). Numbers of participants with endocrinopathy at each time point are reported. Please note the small numbers of participants with available data.
groups
  1. description
    Patients with gross total resection (GTR)/no evidence of metastatic (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.
    id
    OG000
    title
    Low-Risk Group
  2. description
    Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.
    id
    OG001
    title
    Intermediate-Risk Group
  3. description
    Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.
    id
    OG002
    title
    High-Risk Group
param Type
NUMBER
population Description
Endocrine screening and growth hormone (GH) testing were done in consenting intermediate risk patients.
reporting Status
POSTED
time Frame
End of induction therapy (approximately 16 weeks from start of treatment), end of therapy (approximately 48 weeks from start of treatment), and 6, 12, 24, 36, 48, and 60 months off therapy
title
Number of Participants With Endocrinopathy
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice